Recent News
Dr. Jack Cush reviews highlights from RheumNow Live 2025 held in Dallas, TX on Feb. 8-9, 2025.



Combination biologics in PsA: are we there yet?
Despite various and efficacious options for management of PsA there is still an unmet need for patients with inadequate responses to current therapies or difficult-to-treat disease. The role of dual biologic therapy targeting different inflammatory pathways has become an area of great interest in the field.
Read Article
Dr. John Cush @RheumNow ( View Tweet)

Dr. John Cush @RheumNow ( View Tweet)

Dr. John Cush @RheumNow ( View Tweet)

Links:

Links:



EGPA in 2025
Formerly classified as an ANCA-associated vasculitis, EGPA is both most commonly ANCA negative and clinically different to the other two ANCA-associated vasculitis conditions, GPA and MPA. The management of EGPA has frequently fallen into the trap of being copied from its more common and well-known cousins. Now, however, we are seeing a discordance and following GPA/MPA management will potentially lead to both over-treatment and suboptimal
Read Article

Links:


Links:

Links:
Dr. John Cush @RheumNow ( View Tweet)


Links: